Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 46

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 46
---
 Elting(4)                   | Former President, Global Orthopedics &             
 Interim Chief Legal Officer                        | $           | 514,800 |

(1) Reflects titles and positions held during the 2024 calendar year. (2) Represents Mr. Gillespie’s annualized salary during the period in January 2024 in which he served as the Company’s Interim Chief Financial Officer. After such time, Mr. Gillespie was employed by the Company as its Chief Accounting Officer. (3) Represents Ms. Burzik’s annualized salary during the period in January 2024 in which she served as the Company’s Interim Chief Executive Officer. (4) Represents Ms. Elting’s annualized salary during the period between January 2024 and July 2024 in which she served as the Company’s President, Global Orthopedics. Cash Performance-Based Incentives – Annual Incentive Program The Committee believes that a significant portion of the compensation for each Section 16 officer and other members of the ELT should be in the form of an annual performance-based cash bonus. These bonuses are provided through our annual cash incentive program, which seeks to align any payout to an executive with actual financial performance of the Company relative to certain pre-established financial and operational performance targets. The Committee is responsible for approving the annual bonus plan design every year. At the outset of each year, the Committee establishes target financial and operational performance goals and a range of performance around the target performance goals for which a bonus would be paid as described below. The plan design, metrics, and threshold, target, and maximum goals support the annual corporate operating plan for the year. The Committee established and approved performance goals at the outset of 2024, which goals were based on (i) net sales, (ii) adjusted EBITDA, (iii) adjusted free cash flow, (iv) new product introduction targets derived from

<div align='center'>37</div>

the Company’s internal budget and financial forecast, and (v) an enterprise CR objective associated with community service hours. The performance goals for individuals serving in the offices of President and Chief Executive Officer, Chief Financial Officer, Chief Legal Officer and Chief People and Business Operations Officer at any point during the year (whether on a full-time or interim basis), were based on Company-wide net sales weighted at 30%, Company-wide adjusted EBITDA weighted at 30%, Company-wide adjusted free cash flow weighted at 25%, new product introductions weighted at 10% and the Company